Medical Oncology, S. Salvatore Hospital, University of L'Aquila, 67100 L'Aquila, Italy ; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Biomed Res Int. 2013;2013:143273. doi: 10.1155/2013/143273. Epub 2013 Nov 6.
Four-drug regimens, such as FIr-B/FOx schedule, can improve efficacy of first-line treatment of metastatic colorectal cancer (MCRC) patients. The present study specifically evaluates feasibility of FIr-B/FOx first-line intensive regimen in fit young-elderly MCRC patients, representing approximately 40% of overall MCRC patients. Activity, efficacy, and safety were equivalent to overall MCRC patients, not significantly different according to KRAS genotype. Clinical outcome was significantly prolonged in liver-limited compared to other/multiple metastatic disease. Safety evaluation of the individual young-elderly patient showed that limiting toxicity syndromes (LTS) in multiple sites were significantly increased, compared to LTS in single site, with respect to non-elderly patients.
四药方案，如 FIr-B/FOx 方案，可以提高转移性结直肠癌（MCRC）患者一线治疗的疗效。本研究专门评估了 FIr-B/FOx 一线强化方案在适合的年轻老年 MCRC 患者中的可行性，这部分患者约占所有 MCRC 患者的 40%。疗效、安全性与所有 MCRC 患者相当，且 KRAS 基因型无显著差异。肝转移患者的临床结局明显优于其他部位转移或多部位转移患者。对个别年轻老年患者的安全性评估显示，与非老年患者相比，多部位限制毒性综合征（LTS）显著增加，而单部位 LTS 则无显著差异。
